Dextenza is an intracanalicular insert that delivers a 0.4mg dose of dexamethasone, a corticosteroid, for up to 30 days following insertion.

A statistically significantly lower risk of dementia or cognitive impairment was observed with GLP-1RAs, though not with SGLT2is or pioglitazone.

Based on these findings, the USPSTF concludes that primary care behavioral counseling interventions to support breastfeeding have a moderate net benefit, with moderate certainty. Interventions or ...

HealthDay News — For patients with Parkinson disease with motor fluctuations, the oral once-daily, selective D1/D5 partial dopamine agonist tavapadon as an adjunct to levodopa increases total daily ON ...

The Food and Drug Administration (FDA) has approved Uplizna ® (inebilizumab-cdon) for the treatment of immunoglobulin G4-related disease (IgG4-RD) in adult patients.

BeiGene has made the decision to end the clinical development program for ociperlimab (BGB-A1217) for the treatment of non-small cell lung cancer ...

Receipt of zoster vaccine reduces probability of new dementia diagnosis over seven-year period by 3.5 percentage points.